tirzepatide ipamorelin Tirzepatide, CJC‑1295/Ipamorelin Tirzepatide – Princeton Peptides (ARL)
Description
Dual GIP/GLP-1 receptor agonist for metabolic research
Tirzepatide users lost about 20% of their body weight, while semaglutide users averaged around 14%
1 of 27 The Gallery above depicts Before and After Images of actual patients
Still, size alone doesnt determine fertility
At 20 mg/mL, the starting dose requires only 12.5 units
At 20 mg/mL, a 1.0 mg dose requires only 5 units on the syringe
